Guangdong Baoli Pharmaceutical's 4 Billion-Dose Formulation Project Commences Construction, Boosting Logistics and Supply Chain

Deep News
01/22

The Guangdong Baoli Pharmaceutical annual 4 billion tablet (capsule) formulation project has officially commenced construction in Shatang Town, Kaiping City, Jiangmen. Located in Shatang Town, Kaiping City, Jiangmen, Guangdong Province, the project is being constructed by CCCC Fourth Harbor Engineering Bureau Co., Ltd. and involves the planned development of three major sections: production support facilities, administrative support buildings, and outdoor ancillary infrastructure. These will encompass core functional areas such as a combined workshop, a comprehensive formulation workshop, a penicillin workshop, and a hazardous materials warehouse.

Beyond its production scale, the project's "engine" effect is also reflected in its high-standard factory buildings and comprehensive supporting facilities, which are expected to attract more upstream and downstream supporting enterprises, R&D institutions, and high-end talent to gather in Kaiping. It is anticipated that this will drive the formation of a complete industrial chain, ranging from active pharmaceutical ingredient supply and excipient production to packaging materials, R&D services, and logistics distribution, thereby upgrading the regional biopharmaceutical industry ecosystem towards greater vitality and resilience.

Liu Chao, Deputy Head of the Project Engineering Department at CCCC Fourth Harbor Engineering Bureau, stated that the project team will strictly adhere to the construction requirements of "high standards, high quality, and high efficiency." A seasoned management team and a pool of technical experts will be assembled to meticulously organize scientific planning and strengthen quality and safety control throughout the entire process, striving to complete the project as soon as possible.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10